- More than half of pediatric patients treated with fidaxomicin for Clostridioides difficile infections were clinically cured within 2 weeks.
- Most patients had underlying medical or surgical conditions.
- Fidaxomicin showed promise as a viable treatment option for CDI, especially in patients with recurrent or refractory disease.
- IBD was associated with a lower rate of clinical cure at day 14.
- Patients with a history of solid organ transplantation had a higher risk of recurrence by day 60.
- Reported adverse events were generally mild, such as abdominal pain, nausea, and vomiting.
- The study provided real-world evidence on fidaxomicin use in pediatric patients, emphasizing the need for prospective trials.
Source: The Journal of Pediatrics
